Page 104 - MemoriaCIBER2019-ENG

104
CIBER Annual report 2019
Treatment. New project with GlaxoSmithKline to find inhibitors of PhoP action. Controlled release systems increase the bactericidal capacity of drugs against intracellular bacteria. Antituberculosis activity of bedaquiline increases when encapsulated in micelles. New project to validate the use of non-steroidal anti-inflammatory drugs and to develop a prognostic factor for TB patients.
Molecular epidemiology. Molecular analysis of MDR M. tuberculosis strains of the last 20 years in Spain. Characte- risation by WGS of more transmissible strains. WGS couples with strain-specific PCR at certain locations (Almería, Panama, Peru, Argentina). Study of properties of more transmissible strains in infection models.
Pneumonia Line
PREvention, DIagnosis and Treatment of pNEUmonia (PREDITNEU)
The existence of the Pneumonia Line enables the prevention, diagnosis and management of respiratory infections to be promoted through the analysis of microorganisms and biomarkers, optimising diagnostic tools and epidemiologi- cal evaluation.
Clinical epidemiology: The emerging lineage 11A-ST6521, arising after a capsular exchange, escapes the action of vac- cines spreading in south-west Europe (Spain, France and Portugal).
The decrease in invasive pneumococcal infection after the introduction of the 13-valent vaccine in children has been offset by the increase in non-vaccine serotypes. The spread of antibiotic resistant lineages (11A and 24F) could jeo- pardize the treatment of severe pneumococcal diseases. Among them, the increase in serotype 11A has been related to the spread of a recombinant PMEN3 clone. The main 11A-PMEN3 lineage appeared after two recombination events between two main pneumococcal clones (11A-ST62 and NT-ST344). This project has produced two high impact publi- cations: Clin Microbiol Infect. 2019 Nov 19. doi: 10.1016 / j. cmi.2019.10.034 [In press]; Eurosurveillance-D-19-00457R1 [In press, EMID: b6d3e5fb9571512b].
Diffuse Respiratory Diseases
Coordinator: Francisco Pérez Vizcaino Pulmonary Hypertension Line
• Organisation and presentations at the 13th Pulmonary Vascular Research Institute Annual World Con- gress (Barcelona 2019).
• Participation in the 1st Symposium of the International Consortium for Genetic Studies in PAH, February 2019.
• 3rd Research Meeting on Pulmonary Hypertension held. Hospital Clínic Barcelona, March 2019.
• Publication of results of combined therapy in patients with pulmonary arterial hypertension (J Heart Lung
Transplant. 2019; 38 (12): 1286-1295; Respir Res. 2019; 20 (1): 208).
• Demonstration of involvement of Kv7 channels in pulmonary vasodilation induced by NO donors and rioci-
guat (Br J Pharmacol. 2019; 176 (13): 2131-2145).
• Demonstration of usefulness of iron oxide nanoparticles in angiography and directed molecular imaging.
(ACS Omega. 2019; 4 (2): 2719-2727.).
• Analysis of the impact of pulmonary artery denervation, physical exercise and rehabilitation on pulmonary
hypertension (Eur Respir J. 2019; 53 (2). Pii: 1800332; Basic Res Cardiol. 2019; 114 (2): 5 ).
• Identification of FIGN as a modulator of low penetration in hereditary pulmonary arterial hypertension (J Med Genet. 2019; 56 (7): 481-490).